SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.08-2.7%Nov 14 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (5126)8/24/1998 11:21:00 AM
From: Anthony Wong  Read Replies (2) of 9523
 
More info from Dow Jones about obesity drug development:

Obesity drugs haven't had stellar results in the
marketplace lately. Roche Holding Ltd.'s Xenical, for
instance, is in regulatory limbo at the Food and Drug
Administration. Roche last year withdrew its marketing
application to address FDA concerns about a possible
link between the drug and breast cancer. In May, the
FDA issued conditional approval for the drug but Roche
must take other steps before it can win final approval.

Nearly a year ago, American Home Products Corp.
pulled its obesity drugs Redux and Pondimin off the
market after the drugs were linked to heart valve and
lung diseases

Pfizer's other obesity research focuses on
neuropeptide-Y, a brain chemical that is the most potent
stimulator of feeding ever discovered. In recent years,
researchers have discovered the receptors in the brain
that "hear" neuropeptide-Y's signal. By blocking the
receptors, Pfizer and other drug makers could create
drugs that shut off carbohydrate cravings.

Other obesity drug development efforts target leptin, a
hormone secreted by fat cells that is believed to send a
signal to the brain that enough fat has been stored and a
person should stop eating.

smartmoney.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News